WebsiteGear Logo Log In
New User? Sign Up
About | Contact | FAQ
  Home News Website Related Online Marketing Tuesday, September 19, 2017 
Add Press Release News | News Feeds Feeds | Email This News Email


Personalized Medicine Markets & Scientific and Commercial Aspects to 2026
Wednesday, September 13, 2017

DUBLIN, September 13, 2017 /PRNewswire/ --

The "Personalized Medicine - Scientific and Commercial Aspects" report from Jain PharmaBiotech has been added to Research and Markets' offering.

http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

This report describes the latest concepts of development of personalized medicine based on pharmacogenomics, pharmacogenetics,pharmacoproteomics, and metabolomics. Basic technologies of molecular diagnostics play an important role, particularly those for single nucleotide polymorphism (SNP) genotyping.

Several players are involved in the development of personalized therapy. Pharmaceutical and biotechnology companies have taken a leading role in this venture in keeping with their future role as healthcare enterprises rather than mere developers of technologies and manufacturers of medicines.

Ethical issues are involved in the development of personalized medicine mainly in the area of genetic testing. These along with social issues and consideration of race in the development of personalized medicine are discussed. Regulatory issues are discussed mainly with reference to the FDA guidelines on pharmacogenomics.

Increase in efficacy and safety of treatment by individualizing it has benefits in financial terms. Information is presented to show that personalized medicine will be cost-effective in healthcare systems. For the pharmaceutical companies, segmentation of the market may not leave room for conventional blockbusters but smaller and exclusive markets for personalized medicines would be profitable. Marketing opportunities for such a system are described with market estimates from 2016-2026.

Profiles of 323 companies involved in developing technologies for personalized medicines, along with 585 collaborations are included in the part II of the report. Finally the bibliography contains over 750 selected publications cited in the report.The report is supplemented by 83 tables and 39 figures.

Key Topics Covered:

Part I: Scientific & Commercial Aspects

Executive Summary

1. Basic Aspects

2. Molecular Diagnostics in Personalized Medicine

3. Pharmacogenetics

4. Pharmacogenomics

5. Role of Pharmacoproteomics

6. Role of Metabolomics in Personalized Medicine

7. Personalized Biological Therapies

8. Personalized Non-pharmacological Therapies

9. Personalized Medicine in Major Therapeutic Areas

10. Personalized Therapy of Cancer

11. Development of Personalized Medicine

12. Ethical, Legal and Regulatory Aspects of Personalized Medicine .

13. Commercial Aspects of Personalized Medicine

14. References

Part II: Companies

14. Companies Involved in Developing Personalized Medicine

For more information about this report visit https://www.researchandmarkets.com/research/5fmwc8/personalized

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/personalized-medicine-markets--scientific-and-commercial-aspects-to-2026-300518903.html

SOURCE Research and Markets



Email This News Email | Submit To Slashdot Slashdot | Submit To Digg.com Digg | Submit To del.icio.us Del.icio.us | News Feeds Feeds

RELATED NEWS ARTICLES
Nav Path Interactive Named The 2017 North America Winner Of Google's Display Innovation Award | Sep 19, 2017
Nav Telcoin announces investment by Mixi co-founder and East Ventures | Sep 19, 2017
Nav Don't Wait to Buy in the 20 Hottest Neighborhoods in the US | Sep 19, 2017
Nav Alzheimer Disease Markets, 2026: New Drugs, Markets and Companies - Profiles of 144 Companies with 92 Collaborations | Sep 19, 2017
Nav Optanix Names Mike Crest as CEO | Sep 19, 2017
Nav JMR Graphics Shares Vinyl Graphic Design Tips for Bus, Trailer, and Transit Wraps: How to Drive Big Results for Your Business | Sep 19, 2017
Nav Ibotta Launches New Performance Marketing Platform to Accelerate Traditional Retailers' Mobile Commerce Efforts | Sep 19, 2017
Nav As Innovative Video Marketing Escalates in China, Tangeche Becomes First Youku NIVA CPM Client, Powered by Mirriad Technology | Sep 19, 2017
Nav China NVH (System, Parts, Materials) Industry Report 2017-2021 Featuring 10 NVH Companies | Sep 19, 2017
Nav "Livin': From the Amsterdam Red Light to the African Bush" by Frankie Hogan Released | Sep 19, 2017
NEWS SEARCH

FEATURED NEWS | POPULAR NEWS
Submit News | View More News View More News